Search

Displaying results 3111 - 3120 of 10000 in total
  1. Drug

    Tioguanine

    go.drugbank.com/drugs/DB00352
    ApprovedInvestigational

    An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.

  2. Drug

    Ozanimod

    go.drugbank.com/drugs/DB12612
    ApprovedInvestigational

    [A189336] In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard … Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease.

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  3. Drug

    Oleoyl-estrone

    go.drugbank.com/drugs/DB04870
    Investigational

    Oleoyl-estrone (OE) is a fatty acid ester of estrone. This hormone occurs naturally and is found circulating in various animal species and humans. … Body protein loss is an unpleasant effect of fat loss by the restriction of calories, and studies show that this drug appears to avoid this effect.

  4. Drug

    Galiximab

    go.drugbank.com/drugs/DB04901
    Investigational

    Galiximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.

  5. Drug

    Voacamine

    go.drugbank.com/drugs/DB04877
    Experimental

    Voacamine is an alkaloid isolated from the bark of the _Pescheria fuchsiae folia_ tree. It is an antimalarial drug approved for use in several African countries.

    Categories: P-glycoprotein inhibitors
  6. Drug

    Clobetasol

    go.drugbank.com/drugs/DB11750
    ApprovedInvestigationalWithdrawn

    Clobetasol is under investigation for the treatment of Scleroderma. Clobetasol has been investigated for the prevention of Psoriasis and Cutaneous Atrophy Due to Corticosteroids.

    Categories: Corticosteroids, Very Potent (Group IV), Cytochrome P-450 Substrates
  7. Drug

    Nirsevimab

    go.drugbank.com/drugs/DB16258
    ApprovedInvestigational

    In addition, nirsevimab was developed as a single-dose treatment for all infants experiencing their first RSV season, whereas palivizumab requires five monthly doses to cover an RSV season. … [A254691] This is due to a modification in the Fc region of nirsevimab that grants it a longer half-time compared to typical monoclonal antibodies.

  8. Drug

    Ginseng

    go.drugbank.com/drugs/DB01404
    ApprovedInvestigationalNutraceutical

    Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties

  9. Drug

    Pralnacasan

    go.drugbank.com/drugs/DB04875
    Experimental

    Pralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).

  10. Drug

    Tolbutamide

    go.drugbank.com/drugs/DB01124
    Approved

    Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C18 SubstratesSynonyms: 1-Butyl-3-(p-tolylsulfonyl)urea, 1-p-Toluenesulfonyl-3-butylurea